Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Istiratumab - Merrimack Pharmaceuticals

Next Previous
Drug Profile

Istiratumab - Merrimack Pharmaceuticals

Alternative Names: MM-141

Latest Information Update: 24 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Adimab
  • Developer Merrimack Pharmaceuticals
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; MTOR protein inhibitors; Proto-oncogene protein c-akt inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Ovarian cancer; Pancreatic cancer; Solid tumours

Most Recent Events

  • 25 Apr 2025 Pharmacodynamics data from preclinical trial in Solid tumours presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
  • 08 Jan 2019 Shire has been acquired and merged into Takeda
  • 25 Jun 2018 Discontinued - Phase-II for Pancreatic cancer (Combination therapy, First-line therapy, Metastatic disease) in Belgium (Parenteral)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top